FDA approves first dermal filler for acne scars; Teva rolls out copy of Pfizer's Zyvox antibiotic;

@FiercePharma: Hello, hep C pricing war: Gilead hits back at AbbVie with exclusive CVS deal. More | Follow @FiercePharma

@CarlyHFierce: NPS is officially up for sale. Will deal-minded Shire bid? Story | Follow @CarlyHFierce

> Suneva Medical won FDA approval for Bellafill, the first dermal filler cleared specifically to treat scarring caused by acne. Report

> Teva Pharmaceutical Industries ($TEVA) rolled out generic versions of two antibiotics in the U.S., including a copy of Pfizer's ($PFE) blockbuster Zyvox. Report

> Bayer HealthCare chose Onco360, a specialty distributor focusing on cancer products, to distribute its cancer drugs Nexavar and Stivarga as part of a limited distribution plan for those meds. Release

> Ariad Pharmaceuticals ($ARIA) inked a licensing deal with Italy-based Angelini Pharma to push its cancer drug Iclusig into 23 markets in Eastern Europe. Report

> After allowing several Big Pharma cancer drugs to be approved without local trials, Indian officials are now asking the makers of those therapies to monitor them for post-marketing safety. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA approves Medtronic's drug-coated balloon, setting up clash with Bard in new U.S. market. Article | Follow @FierceMedDev

@EmilyWFierce: Covidien shareholders approve proposed $43B merger with Medtronic; Medtronic shareholder vote TK. Article | Follow @EmilyWFierce

> Qualcomm to connect medical devices to cloud for Walgreens, Novartis. Report

> Health devices take the stage at Consumer Electronics Show. Story

Biotech News

@FierceBiotech: A record year for biotech inspires some great expectations for 2015. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Third Rock-backed GBT bags $48M round, plots upcoming IPO. Report | Follow @JohnCFierce

@DamianFierce: $GUD's CEO says he got so many calls about FDA priority review voucher that Knight may make a business out of it. More from Bloomberg | Follow @DamianFierce

> Tracon eyes a $57.5M IPO to get its cancer drug into Phase III. Report

> Gilead buys its way into the blockbuster NASH race with $470M deal. Article

> The biotech blitz: Seres Health lands $65M for PhIII C. diff push. News

> CytomX bags $20M for its novel antibodies with Pfizer leading the charge. Article

> Moderna hauls in $450M to push its pioneering approach to mRNA. News

Biotech Research News

> Mouse study points to a particular T cell target for diabetes, insulin resistance. Report

> Cold Spring Harbor scientists find a biomarker for p53 cancer mutations. Item

> Positive primate study for Parkinson's inspires a rally for Minerva. Story

> Johns Hopkins stem cell team tests out CRISPR tech, with encouraging results. More

> CHOP scientists herald new approach to neurodegenerative diseases. Article

Pharma Manufacturing News

> Hospira recalls cancer med that was focus of warning letter. More

> FDA delays enforcing track-and-trace rules by four months. Report

> FDA sends warning letter to China's Novacyl Wuxi. News

> Patients had problems after being given IVs intended for training, FDA reports. Story

> Valeant says inhaled drug used on infants may be contaminated. Article

And Finally... Here are some unintended consequences: Bayer issues a 3-bottles-for-$10 coupon on Bayer Aspirin. Wal-Mart's price is $2.17. So, coupon users pocket the difference in cash. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.